Evidence map›Paper›PMID 38646716›Full record

ArticleCell transplantation

From the Clinical to the Bench: Exploring the Insulin Modulation Effects of Tacrolimus and Belatacept.

Quentin Perrier, Cécile Cottet-Rouselle, Marine de-Beaumont, Johan Noble, Sandrine Lablanche

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Quentin PerrierGrenoble Alpes University, INSERM U1055, LBFA, Pharmacy Department, Grenoble Alpes University Hospital, Grenoble, France.ORCID 0000-0002-7445-7922
Cécile Cottet-RouselleGrenoble Alpes University, INSERM U1055, LBFA, Grenoble, France.
Marine de-BeaumontGrenoble Alpes University, INSERM U1055, LBFA, Grenoble, France.
Johan NobleGrenoble Alpes University, INSERM, IAB, Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble Alpes University Hospital, Grenoble, France.
Sandrine LablancheGrenoble Alpes University, INSERM U1055, LBFA, Diabetology and Endocrinology Department, Grenoble Alpes University Hospital, Grenoble, France.
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Calcineurin inhibitors (CNIs) are critical in preventing rejection posttransplantation but pose an increased risk of post-transplant diabetes (PTD). Recent studies show that late conversion from CNIs to belatacept, a costimulation blocker, improves HbA1c in kidney transplant recipients with PTD or

Indexed as

AbataceptImmunosuppressive AgentsInsulinTacrolimusAnimalsCell LineCell SurvivalDiabetes MellitusHumansInsulin SecretionIslets of LangerhansIslets of Langerhans TransplantationMaleMiceRatsAbataceptImmunosuppressive AgentsInsulinTacrolimusbelataceptbeta cellscalcineurin inhibitorfunctionalityisletstacrolimusviability

Identifiers

PMID38646716
PMCPMC11034418
OpenAlexW4395009536

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.